Fig. 4.

Performance on the VPVD reversal task after dopamine receptor antagonism. D2-like receptor antagonism (raclopride; 0.03 mg/kg; n = 13) and D1-like receptor antagonism (SCH39166; 0.05 mg/kg, n = 14) had no significant effect versus vehicle treatment (saline; n = 20). a %Correct over each of 10 sessions. b No effect on number of errors on standard A− < B+ trials committed during each of three learning phases. c, d Performance on probe trials. Raclopride and SCH39166 did not significantly affect learning overall on either positive (B+ > C_50/50) or negative (A− < C_50/50) trials. The graphs show mean ± SEM for each dose and session